CAPS and neoplasm: In contrast, the LN229R group with concurrent FOSL1 knockdown and PRMT1 overexpression demonstrated accelerated tumor progression in comparison to the group featuring FOSL1 knockdown, PRMT1 overexpression, and CAPS knockdown (Fig. 8b-d).